VOR Earnings & Financial Statements
Vor Biopharma Inc.
$18.75
-$0.31(-1.63%)
35
Overall
60
Value
30
Tech
15
Quality
Market Cap
$1.11B
Volume
926.92K
52W Range
$6.50 - $33.42
Target Price
$37.43
VOR earnings and financial statements: Vor Biopharma Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
VOR Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating income | -$371.64M | -$121.19M | -$126.04M | -$93.42M | -$69.02M |
| EBITDA | -$693.08M | -$113.41M | -$122.54M | -$89.61M | -$67.50M |
| Net income | -$695.98M | -$116.91M | -$117.86M | -$92.09M | -$68.90M |
| EPS (diluted) | $-70.50 | $-34.00 | $-35.00 | $-46.60 | $-42.00 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $464.13M | $142.89M | $198.13M | $299.37M | $242.59M |
| Total liabilities | $628.44M | $46.23M | $47.40M | $48.76M | $26.33M |
| Shareholders’ equity | -$164.31M | $96.66M | $150.72M | $250.61M | $216.26M |
| Cash and equivalents | $396.49M | $81.95M | $31.36M | $57.71M | $119.80M |
| Long-term debt | $2.72M | $27.61M | $31.83M | $35.64M | $16.17M |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$142.71M | -$99.66M | -$100.29M | -$85.14M | -$69.14M |
| Capital expenditure | -$142.0K | -$229.0K | -$1.07M | -$8.46M | -$3.89M |
| Free cash flow | -$143.65M | -$99.89M | -$101.36M | -$93.61M | -$73.04M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | VOR | $18.75 | -1.6% | 926.92K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |